Trial · NCT03525002
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Interaction between FTO genotype and treatment on change in body weight. | 18 weeks | Interaction between FTO (single nucleotide peptide) SNP rs8050136 genotype and treatment (bromocriptine or placebo) on change in body weight. |
| Secondary | Effect of bromocriptine vs. placebo on body weight | 18 weeks | |
| Secondary | Effect of bromocriptine vs. placebo on dietary intake | 18 weeks | Dietary intake will be monitored by food diaries |
| Secondary | Effect of bromocriptine vs. placebo on processing of food cues in the brain | 18 weeks | Processing of food cues in the brain will be assessed by functional magnetic resonance imaging before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on body fat distribution | 18 weeks | Body fat distribution will be assessed by magnetic resonance imaging and magnetic resonance spectroscopy before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on whole body insulin sensitivity | 18 weeks | Whole body insulin sensitivity will be quantified from 5 point 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on insulin secretion | 18 weeks | Insulin secretion will be quantified from 5 point 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on glucose tolerance | 18 weeks | Glucose tolerance will be assessed by 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on brain insulin sensitivity | 18 weeks | Brain insulin sensitivity will be assessed by functional magnetic resonance imaging combined with intranasal insulin administration before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on resting energy expenditure | 18 weeks | Resting energy expenditure will be assessed by indirect calorimetry before and after treatment with bromocriptine or placebo |
| Secondary | Effect of bromocriptine vs. placebo on physical activity | 18 weeks | Physical activity will be monitored using an accelerometer |
| Secondary | Effect of bromocriptine vs. placebo on serum prolactin concentrations | 18 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03525002/registered